Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia

Psychiatry Research - Neuroimaging

Volumn 107, Issue 3, 2001, Pages 135-149

  Bustillo, Juan R ^a   Lauriello, John ^a   Rowland, Laura M ^a   Jung, Rex E ^a   Petropoulos, Helen ^a   Hart, Blaine L ^b   Blanchard, Jack ^a   Keith, Samuel J ^a   Brooks, William M ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Frontal lobe; Magnetic resonance spectroscopy; N acetyl aspartate; Neurotoxicity; Striatum

Indexed keywords

CHOLINE; CLOZAPINE; CREATINE; CREATINE PHOSPHATE; HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CAUDATE NUCLEUS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG MECHANISM; FEMALE; FRONTAL LOBE; HUMAN; LONG TERM CARE; MALE; MOTOR ACTIVITY; NEUROCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CAUDATE NUCLEUS; CLOZAPINE; FEMALE; FRONTAL LOBE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0035479156     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(01)00102-0     Document Type: Article

References (70)

1. Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia
2. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration standard
3. A rating scale for drug-induced akathisia
4. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy
5. 1H-MRS studies in vivo
6. The effects of haloperidol on synaptic patterns in the rat striatum
7. The effect of treatment with antipsychotic drugs on brain N-acetyl-aspartate measures in patients with schizophrenia
8. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopy imaging
9. 1H-MRS in vivo
10. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus
11. 1H-MRS differentiates white matter hyperintensities in subcortical arteriosclerotic encephalopathy from those in normal elderly
12. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia
13. 1H-Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates
14. Neuroleptic medications inhibit complex I of the electron transport chain
15. Schizophrenia: Improving outcome
16. The action of chlorpromazine and imipramine in rat mitochondria
17. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naïve patients with schizophrenia
18. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine
19. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs
20. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy
21. H-magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naïve, chronic schizophrenia
22. Biochemical and behavioral properties of clozapine
23. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?
24. Decreased left frontal lobe N-acetylaspartate in schizophrenia
25. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy
26. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: Preliminary report
27. Schizophrenia as a chronic brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia
28. Neurotransmitters
29. Conventional antipsychotic medications for schizophrenia
30. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia
31. Proton MR spectroscopic findings correspond to diffuse neuropsychological function in traumatic brain injury
32. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia
33. Heritability heightens brain metabolite differences in schizophrenia
34. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
35. A follow-up magnetic resonance imaging study of schizophrenia
36. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect
37. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol
38. Biochemical markers of cognition: A proton MR spectroscopy study of normal human brain
39. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy
40. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
41. Hippocampal pathology in schizophrenia: Magnetic resonance imaging and spectroscopy studies
42. The effects of chronic haloperidol treatment on dendritic spines in the rat striatum
43. Changes in caudate volume with neuroleptic treatment
44. The schedule for the deficit syndrome: An instrument for research in schizophrenia
45. Changes in rCBF after acute challenge with haloperidol and olanzapine in patients with schizophrenia
46. Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia
47. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo
48. 1H-MRS) of the hippocampal formation in schizophrenia: A pilot study
49. Evidence for cell loss in corpus striatum after long-term treatment with neuroleptic drug (flupentixol) in rats
50. 18FDG] PET
51. Automated T2 quantitation in neuropsychiatric lupus erythematosus: A marker of active disease
52. SVD-based quantification of magnetic resonance signals
53. Childhood-onset schizophrenia. Progressive ventricular change during adolescence
54. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum
55. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
56. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure
57. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: A preliminary report
58. A rating scale for extrapyramidal side-effects
59. Quantitation of automated single-voxel proton MRS using cerebral water as an internal reference
60. 1HMR spectroscopy in childhood-onset schizophrenia
61. N-acetylation of L-aspartate in the nervous system: Differential distribution of a specific enzyme
62. Time and frequency domain analysis of NMR data compared: An application to 1-D1H spectra of lipoproteins
63. Clinical magnetic resonance spectroscopy of brain, heart, liver, kidney, and cancer. A quantitative approach
64. Is schizophrenia a progressive neurodevelopmental disorder? Towards a unitary pathogenetic mechanism
65. The effects of early and sustained intervention on the long-term morbidity of schizophrenia
66. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls